CL4H6
Based on 1 publication(s) in Google Scholar
CL4H6 is a pH-sensitive cationic lipid. CL4H6 is the main component of lipid nanoparticles (LNPs), which can be used to target and deliver siRNA, and induces a potent gene-silencing response.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 98.32%
- No. CAS: 2256087-35-9
- Fòrmula: C59H113NO5
- Peso molecular:916.53
-
Almacenamiento:Pure form -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
Metabolism/Protease Compound Library
HY-L012
-
Anti-Cancer Compound Library
HY-L025
-
Lipid Compound Library
HY-L043
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Liposome Library
HY-L214
-
Ionizable Lipid Compound Library
HY-L251
Publications Citing Use of MedChemExpress (MCE) CL4H6
More
Actividad biológica
CL4H6 potent targeting of hepatocytes and endosomal escape, to safely and efficiently deliver a myocardin-related transcription factor/serum response factor (MRTF/SRF)-B siRNA into human conjunctival fibroblasts[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
No. CAS 2256087-35-9
-
Appearance Viscous Liquid
-
Peso molecular 916.53
-
Fòrmula C59H113NO5
-
Color Colorless to light yellow
-
SMILES
CCCN(CCC)CCCCC(CCCCCCOC(CCCCCCC/C=C\CCCCCCCC)=O)(O)CCCCCCOC(CCCCCCC/C=C\CCCCCCCC)=O
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Pure form -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Br J Pharmacol
Reprogramming tumour-associated macrophages in breast cancer via si-FOXM1-loaded lipid nanoparticles enhances immune checkpoint inhibitor efficacy. [Abstract]2026 Jun;183(11):3049-3073. PMID: 41723880
Solvente y solubilidad
DMSO : 100 mg/mL (109.11 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (2.73 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (267 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Amisha Sanghani, et al. Novel PEGylated Lipid Nanoparticles Have a High Encapsulation Efficiency and Effectively Deliver MRTF-B siRNA in Conjunctival Fibroblasts. Pharmaceutics. 2021 Mar 13;13(3):382. [Content Brief]
[2]. Nour Shobaki, et al. Manipulating the function of tumor-associated macrophages by siRNA-loaded lipid nanoparticles for cancer immunotherapy. J Control Release. 2020 Sep 10;325:235-248. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.0911 mL | 5.4554 mL | 10.9107 mL | 27.2768 mL |
| 5 mM | 0.2182 mL | 1.0911 mL | 2.1821 mL | 5.4554 mL | |
| 10 mM | 0.1091 mL | 0.5455 mL | 1.0911 mL | 2.7277 mL | |
| 15 mM | 0.0727 mL | 0.3637 mL | 0.7274 mL | 1.8185 mL | |
| 20 mM | 0.0546 mL | 0.2728 mL | 0.5455 mL | 1.3638 mL | |
| 25 mM | 0.0436 mL | 0.2182 mL | 0.4364 mL | 1.0911 mL | |
| 30 mM | 0.0364 mL | 0.1818 mL | 0.3637 mL | 0.9092 mL | |
| 40 mM | 0.0273 mL | 0.1364 mL | 0.2728 mL | 0.6819 mL | |
| 50 mM | 0.0218 mL | 0.1091 mL | 0.2182 mL | 0.5455 mL | |
| 60 mM | 0.0182 mL | 0.0909 mL | 0.1818 mL | 0.4546 mL | |
| 80 mM | 0.0136 mL | 0.0682 mL | 0.1364 mL | 0.3410 mL | |
| 100 mM | 0.0109 mL | 0.0546 mL | 0.1091 mL | 0.2728 mL |
CL4H6 Related Classifications
HY-139305 Related Classifications
Powered by Bioz